The US Food and Drug Administration’s regulatory policy for homeopathic drugs is targeted in a challenge to the agency’s authority leveraging the Supreme Court’s decision striking the Chevron doctrine of deference.
Challenge To US Homeopathic Drugs Regulation Rings Post-Chevron And OTC Monograph Bells
Supreme Court’s Loper Bright “decision is central to this case,” says Jonathan Emord, attorney representing Alliance for Natural Health USA and Meditrend Inc. in a complaint filed in US District Court for the District of Columbia.
